<?xml version="1.0" encoding="UTF-8"?>
<p id="p0275">Also, despite entecavir and TDF compound patents having expired in 2010 and 2017 respectively, there are major discrepancies in prices across LMICs (
 <xref rid="bib71" ref-type="bibr">71</xref>, 
 <xref rid="bib72" ref-type="bibr">72</xref>). Since 2011, TDF patents were licensed to the Medicines Patent Pool including for the indication of hepatitis B. Consequently, quality assured low price TDF has been available well before the patent expired. Today, a yearâ€™s course of TDF can be purchased for as little as US$32 and entecavir for US$427 (
 <xref rid="bib73" ref-type="bibr">73</xref>). However, few countries have taken advantage of these prices; even in countries where TDF is licensed, procurement still occurs through private mechanisms at unaffordable prices. Inclusion of TDF and entecavir in the national essential medicines list supported by the WHO 20
 <sup>th</sup> essential medicines list recommendation allows countries with high prevalence to leverage generic pharmaceutical companies to supply drug at affordable prices, or generate local production markets to boost revenue and drive down costs (Supplementary Table 1)(
 <xref rid="bib26" ref-type="bibr">26</xref>).
</p>
